A Study With Pentasa in Patients With Active Crohn's Disease
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose
and a 4 g evening dose is efficacious in active mild to moderate CD.